Highest-materiality recent filing
Chemours agrees to $22.5M penalty and $90M in PFAS mitigation projects to settle EPA claims
Civil penalty of $22.5M payable in three annual installments starting within 30 days of court approval; $15M already accrued.
Chemours Q1 net loss widens to $29M; adjusted EBITDA up 2% to $169M
Net sales $1.381B, up 1% YoY; TSS segment posted record Q1 with double-digit Opteon growth.
Shareholders approve 2026 Equity Plan, elect 11 directors at annual meeting
2026 Equity Plan approved with ~96.7% of votes cast; authorizes 6,375,275 shares for issuance.
Chemours issues $700M 7.875% senior notes due 2034; refinances 2027 and 2028 notes
Closed private offering of $700M aggregate principal of 7.875% senior notes due 2034.
Chemours Q4 net loss widens to $47M; full year 2026 outlook: Adj. EBITDA $800M-$900M
Q4 net loss $47M (-$0.31/diluted) vs loss $11M (-$0.08) YoY; adjusted net income $7M ($0.05) vs $14M ($0.09).
Chemours agrees to sell Taiwan land for $360M, proceeds to reduce debt
Total gross cash proceeds of approximately $360 million from sale of former TiO2 site in Kuan Yin, Taiwan.
Chemours Q3 net income $60M vs loss prior year; adjusted EBITDA $195M down 3%
Net income of $60M ($0.40/share) reverses prior-year loss of $32M; adjusted net income $30M ($0.20) vs $61M.
Chemours Q2 net loss $381M; adjusted EBITDA up 22% to $253M; NJ PFAS settlement reached
Net loss of $381M ($2.54 diluted EPS) vs net income $60M ($0.39) in Q2 2024; adjusted net income $87M ($0.58).
Chemours, DuPont, Corteva agree to $875M NJ PFAS settlement; Chemours share ~$250M PV
Total $875M cash over 25 years; pre-tax PV ~$500M (8% discount); Chemours 50% (~$250M PV).
Chemours Q1 net loss of $4M vs profit $54M; adjusted EBITDA $166M; cuts dividend
Net loss $4M, diluted EPS -$0.03 vs net income $54M, EPS $0.36 YoY.
Chemours reports Q4 2024 net loss of $8M, provides FY2025 EBITDA guidance of $825-975M
Q4 Net Sales $1.4B flat YoY; Net Loss $8M ($0.05 diluted) vs prior year loss $18M.
Chemours prices $600M 8% senior notes due 2033 to refinance 2026 notes
$600M principal of 8.000% senior unsecured notes due 2033 priced in private offering.
Chemours Q3 net loss $27M on $56M impairment; adjusted EPS $0.40; TSS Opteon sales up 21%
Net loss of $27M ($0.18/diluted share) due to $56M non-cash impairment of APM goodwill.
Chemours Q2 net income $70M vs prior loss; adj EBITDA down 36%
Net sales $1.5B (-6% YoY); net income $70M ($0.46 diluted EPS) vs prior-year net loss $376M ($2.52 loss).
Chemours names Shane Hostetter as CFO effective July 1, 2024
Hostetter joins from Quaker Houghton, where he served as CFO since April 2021.
Paused production at Altamira TiO2 facility in Mexico due to severe regional drought.
Chemours Q1 earnings: net sales $1.35B (-12% YoY), net income $52M, adj EBITDA $193M
Net sales $1.35B, down 12% YoY; volumes -6%, price -5%.
Chemours CFO Lock resigns amid accounting review; gets extended options, no severance
Resigned as SVP & CFO effective April 23, 2024; no severance, no 2023 or 2024 annual incentive.
Chemours Q4 adjusted EPS $0.31 vs $0.00 YoY; full year net loss $238M on $764M litigation charges
Q4 2023 net sales $1.4B (+2% YoY); full year net sales $6.0B (-11% YoY).
Chemours reveals ~$100M Q4 pay delay, ~$260M early receivables; 4 material weaknesses found
Audit committee review found Q4 2023 vendor payments of up to ~$100M delayed into Q1 2024.
Chemours appoints Denise Dignam as President and CEO, replacing Mark Newman
Denise Dignam named President and CEO effective March 22, 2024; she was interim CEO since February 2024.
Chemours receives NYSE noncompliance notice for delayed 10-K filing
NYSE notified Chemours on March 18, 2024 that it is not in compliance with Section 802.01E for failure to timely file its 2023 Form 10-K.
Senior management placed on administrative leave for delaying vendor payments from Q4 2023 to Q1 2024 and accelerating receivables into Q4 2023 to meet free cash flow targets.
Chemours places CEO, CFO, and CAO on leave; appoints interim leaders
CEO Mark Newman, CFO Jonathan Lock, and CAO Camela Wisel placed on administrative leave pending Audit Committee review.
CEO Mark Newman, CFO Jonathan Lock, Controller Camela Wisel placed on administrative leave pending internal review.
Earnings release postponed from Feb 14 to Feb 28, 2024; conference call moved to Feb 29.
Chemours agrees to $110M PFAS settlement with Ohio; records $67.5M pre-tax charge
Chemours, DuPont, and Corteva settle Ohio PFAS claims for $110M; Chemours share $55M.
On March 9, 2025, Guillaume Pepy notified the Board of Directors (the “Board”) of The Chemours Company (the “Company”) of his decision not to seek re-election to the Board at the Company’s 2025 Annual Meeting of Shareholders, when his current term expires.
On February 13, 2025, Curtis V. Anastasio notified the Board of Directors (the "Board") of The Chemours Company (the "Company") of his decision not to seek re-election to the Board at the Company's 2025 Annual Meeting of Stockholders, when his current term expires.
appointed Leslie M. Turner as a member of the Board, effective February 19, 2025.
On January 3, 2025, the Board of Directors (the “Board”) of The Chemours Company (the “Company”) appointed Joseph D. Kava as a member of the Board, effective January 3, 2025.
On July 23, 2024, David A. Will was appointed as Controller and Chief Accounting Officer (principal accounting officer) of The Chemours Company (the “Company”) effective as of August 12, 2024.
On June 12, 2024, the Board of Directors (the “Board”) of The Chemours Company (the “Company”) appointed Livingston “Tony” Satterthwaite as a member of the Board, effective June 12, 2024.
Mr. Hostetter succeeds Matthew Abbott, who has served as the Interim Chief Financial Officer (principal financial and accounting officer) since February 28, 2024. Mr. Abbott will continue serving as the Company’s Senior Vice President & Chief Enterprise Transformation Officer
On May 31, 2024, the Board of Directors (the “Board”) of The Chemours Company (the “Company”) appointed Shane Hostetter as Chief Financial Officer, effective as of July 1, 2024.
On April 23, 2024, Jonathan S. Lock resigned from all positions with The Chemours Company (the “Company”).
Mark Newman, who resigned from his officer and director positions with the Company, also effective as of March 22, 2024.
The Board of Directors (the “Board”) of The Chemours Company (the “Company”) has named Denise Dignam, formerly Interim Chief Executive Officer, as President and Chief Executive Officer and as a member of the Board, effective as of March 22, 2024.
the Board placed President and Chief Executive Officer Mark Newman, Senior Vice President and Chief Financial Officer Jonathan Lock and Vice President, Controller and Principal Accounting Officer Camela Wisel on administrative leave
Max materiality 0.90 · Median 0.60 · Most common event leadership